Arvinas, Inc.
ARVN
Jodie situation report
Arvinas, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- ARVN's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ARVN's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ARVN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.partnerMay 11, 2026 ▾
“In September 2025, we and Pfizer, Inc.”
NVSNovartis AGinvesteeMay 11, 2026 ▾
“In the second quarter of 2024, we completed a transaction with Novartis Pharma AG, or Novartis, which comprised a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement.”
Depended on by
PFEPfizer, Inc.partnerMay 5, 2026 ▾
“37 Approvals: PRODUCT INDICATION DATE/MARKET Veppanu (vepdegestrant) (a) Treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endo…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARVN is currently a Follower in the organic co-movement group Healthcare & Consumer Cyclical. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ARVN; it is not active in the latest market snapshot.